Public summary
Drug development is a highly regulated environment. Identifying the need for an independent, academic-led centre of excellence in research and training of pharmacokinetics, we established the Centre for Applied Pharmacokinetic Research (CAPKR) to engage in problems of generic interest to the Pharmaceutical Industry. CAPKR has been highly influential by informing regulatory practice in Europe and the USA, by establishing and optimising industrial practices related to drug development, particularly those related to drug-drug interactions, by reducing the usage of animals in research and by allowing the commercial development and extensive use of simulation software tools for quantitative prediction of pharmacokinetics in order to improve patients’ safety.| Impact date | 2014 |
|---|---|
| Category of impact | Health impacts |
| Impact level | Adoption |
Related content
-
Research output
-
Quantitative characterization of therapeutic index: Application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships
Research output: Contribution to journal › Article › peer-review
-
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance’, Biochemical Pharmacology
Research output: Contribution to journal › Article › peer-review
-
Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential - Toward a consensus
Research output: Contribution to journal › Article › peer-review
-
Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases
Research output: Contribution to journal › Article › peer-review
-
CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions
Research output: Contribution to journal › Article › peer-review
-
Physiologically Based Pharmacokinetics in Drug Development and Regulatory Science: A workshop report.
Research output: Chapter in Book/Conference proceeding › Conference contribution